Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy

West Coast Retina Medical Group, Inc.40 enrolled

Overview

To obtain a genotypic analysis of patients with chronic exudative age-related macular degeneration noted to have subretinal or intraretinal edema despite continuous monthly Anti-VEGF therapy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Wet AMD

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Ability to provide written informed consent for participation in this study * Subjects diagnoses of neovascular AMD who are on a monthly anti-VEGF regimen (have had \>10 or more ranibizumab and/or bevacizumab injections within the last year) and who still have intra-retinal or subretinal fluid as confirmed by the Investigator Exclusion Criteria: * Subjects with a Pigment Epithelial Detachment Exclusively * Subjects with Serous Pigment Epithelial Detachments * Subjects with history of the following: idiopathic polypoidal choroidal vasculopathy * pathologic degenerative myopia * central serous chorioretinopathy * familial drusen * adult onset foveal pattern dystrophy

Locations (1)

West Coast Retina Medical Group, Inc.

San Francisco, California, United States

Outcomes

Primary Outcomes

Genetic analysis of patients with chronic wet age-related macular degeneration despite continuous anti-VEGF treatment

Time frame: This is a one time only blood draw.

Secondary Outcomes

To evaluate demographic and clinical characteristics in patients treated with anti-VEGF therapy who fail to respond completely.

Time frame: This is a one time only blood draw and assessment of clinical characteristics.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.